Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin

Shafique, Muhammad Ashir; Haseeb, Abdul; Siddiq, Mohammad Arham; Mussarat, Abdullah; Rangwala, Hussain Sohail; Mustafa, Muhammad Saqlain

doi:10.2147/cmar.s418009

Cited by 4 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While clinical management of early-stage UCC has seen significant improvements in the past decade, treatment of locally advanced and mUCC remains difficult [14]. Recently, a number of strategies and therapies have been developed for the treatment of advanced UCC.…”

Section: Novel Approaches For Urothelial Cancersmentioning

confidence: 99%

Current and Emerging Strategies to Treat Urothelial Carcinoma

Rani,

Ignatz-Hoover,

Rana

et al. 2023

Cancers

View full text Add to dashboard Cite

Urothelial cell carcinoma (UCC, bladder cancer, BC) remains a difficult-to-treat malignancy with a rising incidence worldwide. In the U.S., UCC is the sixth most incident neoplasm and ~90% of diagnoses are made in those >55 years of age; it is ~four times more commonly observed in men than women. The most important risk factor for developing BC is tobacco smoking, which accounts for ~50% of cases, followed by occupational exposure to aromatic amines and ionizing radiation. The standard of care for advanced UCC includes platinum-based chemotherapy and programmed cell death (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors, administered as frontline, second-line, or maintenance therapy. UCC remains generally incurable and is associated with intrinsic and acquired drug and immune resistance. UCC is lethal in the metastatic state and characterized by genomic instability, high PD-L1 expression, DNA damage-response mutations, and a high tumor mutational burden. Although immune checkpoint inhibitors (ICIs) achieve long-term durable responses in other cancers, their ability to achieve similar results with metastatic UCC (mUCC) is not as well-defined. Here, we discuss therapies to improve UCC management and how comprehensive tumor profiling can identify actionable biomarkers and eventually fulfill the promise of precision medicine for UCC patients.

show abstract

Section: Novel Approaches For Urothelial Cancersmentioning

confidence: 99%

Current and Emerging Strategies to Treat Urothelial Carcinoma

Rani,

Ignatz-Hoover,

Rana

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The clinical management of early-stage BLCA has signi cantly improved in the past decade, and some BLCA patients can achieve a cure (2). However, the management of locally advanced and metastatic BLCA continues to pose signi cant challenges, with a low ve-year survival rate (3). Recently, many strategies have been developed for the treatment of advanced BLCA, among which immune checkpoint inhibitors (ICIs) are worth mentioning (4).…”

Section: Introductionmentioning

confidence: 99%

CXCL10 could be a prognostic and immunological biomarker in bladder cancer

殷,

mou,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction As proteins that promote immune cell differentiation, chemokines have attracted great interest regarding their role in anti-tumor immune responses within the cancer environment. However, the exact role of CXCL10, a chemokine, in bladder cancer (BLCA) is still not fully elucidated. Method In the present study, we employed bioinformatics approaches to examine the expression pattern,prognostic value, and immune infiltration of CXCL10 in BLCA. Furthermore, we focused on examining the impact of CXCL10 on immune therapy in BLCA. Additionally, we validated the expression of CXCL10 in various BLCA cell lines using PCR techniques. Results We observed an upregulation of CXCL10 in BLCA tissues as well as in different cell lines. Additionally, upregulation of CXCL10 indicates a better prognosis for BLCA patients. ESTIMATE and CIBERSORT algorithms suggest that CXCL10 is closely associated with the immune microenvironment of BLCA. Through multiple immune therapy cohorts, we also identified that CXCL10 has shown promising predictive value for assessing theefficacy of immune therapy in in BLCA. Conclusion Our study indicates that CXCL10 has the potential to serve as a favorable prognostic factor and is strongly associated with immune infiltration in BLCA.

show abstract

Emerging Novel Therapies to Treat Urothelial Carcinoma

Rani¹,

Ignatz-Hoover²,

Rana³

et al. 2023

Preprint

View full text Add to dashboard Cite

Urothelial cell carcinoma (UCC, bladder cancer) remains a difficult to treat malignancy with rising incidence worldwide. In the U.S., UCC is the sixth most incident neoplasm and ~90% of diagnoses are made in those &gt;55 years of age, ~four times more commonly observed in men than women. The most important risk factor for developing bladder cancer is tobacco smoking, which accounts for ∼50% of cases followed by occupational exposure to aromatic amines and ionizing radiation. The standard of care for advanced UCC includes platinum-based chemotherapy and programmed cell death (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors, administered as frontline, second-line, or maintenance therapy. UCC is highly aggressive and remains generally incurable since these cancers are associated with intrinsic and acquired drug resistance. UCC is highly lethal in the metastatic state and characterized by genomic instability, high PD-L1 expression, DNA damage-response mutations, and high tumor mutational burden. Although immune checkpoint inhibitors (ICIs) achieve long-term durable responses in other cancers, their ability to achieve similar results with metastatic UCC (mUCC) is not as well-defined. Here, we discuss the novel therapies to improve the management of mUCC.

show abstract

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin

Cited by 4 publications

References 52 publications

Current and Emerging Strategies to Treat Urothelial Carcinoma

Current and Emerging Strategies to Treat Urothelial Carcinoma

CXCL10 could be a prognostic and immunological biomarker in bladder cancer

Emerging Novel Therapies to Treat Urothelial Carcinoma

Contact Info

Product

Resources

About